Star Combo Pharma Ltd. (S66) AI Stock Analysis

• Market Cap: AU$28.35M
• Dividend Yield: 1.76%
• Average Volume (3M): 17.93K
• Price to Earnings (P/E): 5.4
• Beta (1Y): -0.11
• Revenue Growth: 6.89%
• EPS Growth: 607.27%
• Country: AU
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.04
• Shares Outstanding: 135,002,980
• 10 Day Avg. Volume: 8,154
• 30 Day Avg. Volume: 17,929
• PEG Ratio: 0.01
• Price to Book (P/B): 0.63
• Price to Sales (P/S): 0.86
• P/FCF Ratio: 2.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 75 Outperform
• Price Target: AU$0.50 ▲(150.00% Upside)

Star Combo Pharma Ltd. receives a strong overall score due to its solid financial performance and attractive valuation. The company's robust cash flow and low leverage enhance its financial stability, while positive technical indicators suggest a favorable market trend. The low P/E ratio and reasonable dividend yield further support the stock's potential for growth and income.

Star Combo Pharma Ltd. Business Overview & Revenue Model

Company Description

Star Combo Pharma Ltd. (S66) is a pharmaceutical and healthcare company based in Australia, specializing in the development and distribution of a wide range of health products, including dietary supplements, over-the-counter medications, and prescription pharmaceuticals. The company operates within the health and wellness sector, focusing on natural and innovative solutions to meet consumer needs. Star Combo Pharma aims to improve health outcomes through high-quality products that are backed by scientific research and development.

How the Company Makes Money

Star Combo Pharma generates revenue primarily through the sale of its healthcare products, which include both prescription and over-the-counter medications, as well as dietary supplements. The company leverages a multi-channel distribution strategy, selling its products through pharmacies, health food stores, and online platforms. Key revenue streams include direct sales to consumers and partnerships with healthcare professionals and retail distributors. Additionally, the company may engage in collaborations or partnerships with other firms for product development and distribution, which can also contribute to its earnings. Factors such as market demand for health products, regulatory approvals, and the effectiveness of its marketing strategies significantly influence its financial performance.

Star Combo Pharma Ltd. Financial Statement Overview

Summary

Star Combo Pharma Ltd. demonstrates solid financial performance with improvements in profitability and cash flow generation. Despite a decline in revenue growth, the company has enhanced its profit margins and maintains a strong balance sheet with low leverage. The positive cash flow trends further strengthen its financial position.

Income Statement

Star Combo Pharma Ltd. has shown a mixed performance in its income statement. The company experienced a decline in revenue growth rate by 6.34% in the latest year, indicating a contraction in sales. However, the gross profit margin improved to 22.55%, reflecting better cost management. The net profit margin also increased significantly to 18.87%, driven by a substantial rise in net income. Despite these improvements, the EBIT margin remains negative, suggesting challenges in operational efficiency.

Balance Sheet

The balance sheet of Star Combo Pharma Ltd. reflects a stable financial position with a low debt-to-equity ratio of 0.10, indicating conservative leverage. The return on equity improved to 13.78%, showcasing enhanced profitability for shareholders. The equity ratio stands at a healthy level, suggesting a strong capital structure. Overall, the balance sheet indicates financial stability with a low risk of financial distress.

Cash Flow

The cash flow statement shows a robust improvement with a free cash flow growth rate of 178.51%, highlighting strong cash generation capabilities. The operating cash flow to net income ratio is 2.04, indicating efficient cash conversion from earnings. The free cash flow to net income ratio is close to 1, suggesting that the company is effectively converting its profits into cash. These metrics reflect a solid cash flow position, supporting future growth and investment opportunities.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	11.90M	27.81M	26.02M	24.70M	22.88M	26.72M
Gross Profit	2.89M	6.27M	5.44M	4.66M	5.61M	4.61M
EBITDA	6.14M	6.64M	2.79M	-2.53M	-126.71K	-6.40M
Net Income	4.97M	5.25M	747.33K	-4.00M	-696.35K	-7.88M
Balance Sheet
Total Assets	48.45M	48.45M	42.82M	42.23M	43.44M	43.32M
Cash, Cash Equivalents and Short-Term Investments	18.11M	18.11M	7.36M	9.49M	10.39M	17.32M
Total Debt	3.93M	3.93M	4.03M	4.19M	4.12M	3.30M
Total Liabilities	10.19M	10.19M	9.30M	8.97M	8.04M	7.13M
Stockholders Equity	38.08M	38.08M	33.32M	33.09M	35.41M	36.19M
Cash Flow
Free Cash Flow	-25.65K	11.55M	-1.76M	-851.83K	-7.21M	-6.93M
Operating Cash Flow	27.67K	11.94M	-316.45K	1.88M	87.11K	331.53K
Investing Cash Flow	-1.38M	-9.72M	-136.79K	-3.23M	-3.24M	-7.53M
Financing Cash Flow	-412.21K	-795.12K	-370.93K	-53.44K	-169.08K	-2.08M

Star Combo Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:S66, the sentiment is Positive. The current price of 0.2 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.21, and above the 200-day MA of 0.16, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.41 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:S66.

Star Combo Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
S66	―	AU$28.35M	5.40	14.70%	1.76%	6.89%	607.27%
Sector *	―	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
LDX	―	AU$157.17M	―	-111.23%	―	12.96%	40.81%
AGH	―	AU$21.04M	-1.41	―	―	-47.30%	82.53%
ZNO	―	AU$18.28M	-4.46	-77.92%	―	17.41%	67.94%
NC6	―	AU$16.40M	-7.65	-1651.76%	―	-100.00%	2.86%
SKN	―	AU$3.15M	―	―	―	12.92%	34.21%

Star Combo Pharma Ltd. Corporate Events

Star Combo Pharma Secures $5 Million Insurance Settlement Post-Factory Fires

Star Combo Pharma Ltd announced the settlement of insurance claims related to damages from two fires at its factory in 2022, resulting in a $5 million payment. This settlement is expected to provide financial relief and stability, potentially enhancing the company’s operational capabilities and market positioning.